EUVIMEDOpdag EUVIMED
Crossref

Inhibition of GRK2 mitigates cisplatin‐induced acute and chronic nephrotoxicity by targeting the NADPH oxidase 4/oxidative stress axis

Fei Duan, Lei Ni, Qianlei Wang, Jie Peng, Xueru Wang, Yin Wang, Shuoshuo Hu, Jiajie Kuai, Xiao Jiang, Qingtong Wang iD, Bingfa Xu, Wei Wei iD and 1 more

British Journal of Pharmacology · 2026-06 · 183 (12) · 3149-3172

DOI: 10.1111/bph.70348 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2026-03-05. Written by Fei Duan and 12 co-authors. Institution: Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medic…. Major MEDLINE topics: Cisplatin, NADPH Oxidase 4, G-Protein-Coupled Receptor Kinase 2, Oxidative Stress. Cited 2 times so far (Crossref); 66 references. Funded by: Key Research and Development Plan of Anhui Province, Key Project of Provincial Natural Science Foundation of Universities in Anhui, Anhui Province Excellent Research and Innovation Team Project.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Cisplatin nephrotoxicity involves oxidative stress, with NADPH oxidase 4 (NOX4) in renal tubular epithelial cells (RTECs) as a potential source of key reactive oxygen species (ROS). Although G protein‐coupled receptor kinase 2 (GRK2) contributes to tissue injury, its regulatory role in cisplatin nephrotoxicity via NOX4 remains undefined. We have investigated the underlying mechanisms of GRK2 in cisplatin‐induced acute and chronic nephrotoxicity. Experimental Approach Hemizygous Grk2 knockout mice and homozygous Grk2 knockout RTECs were utilised. The GRK2–NOX4 interaction was investigated by co‐immunoprecipitation or glutathione S‐transferase pull‐down. Kinase assays and ubiquitination experiments were performed to investigate the regulatory effect of GRK2 on the phosphorylation and ubiquitination of NOX4. Acute, sub‐chronic and chronic cisplatin models, as well as syngeneic tumour models, evaluated the renoprotection afforded by the GRK2 inhibitor CP‐25 and its impact on chemotherapy efficacy. Key Results Grk2 deficiency attenuated cisplatin‐induced nephrotoxicity in vivo and reduced RTEC death and epithelial–mesenchymal transition (EMT) in vitro. Grk2 knockout or knockdown downregulated NOX4 expression, which repressed NOX4‐mediated ROS release and oxidative stress, preventing cisplatin‐induced RTEC death and EMT. GRK2 promoted NOX4 phosphorylation and suppressed ubiquitin‐mediated degradation, thereby increasing NOX4 stability and ROS production. CP‐25 effectively ameliorated cisplatin‐induced nephrotoxicity, suppressed oxidative stress, and reduced renal apoptosis and EMT without compromising its anticancer efficacy. These protective effects also were observed in vitro. Conclusion and Implications GRK2 plays a crucial role in cisplatin‐induced nephrotoxicity by modulating NOX4, suggesting that targeting GRK2 is an effective renoprotective strategy for cisplatin‐based cancer therapy.

Subjects

MeSH terms (MEDLINE)

CisplatinNADPH Oxidase 4G-Protein-Coupled Receptor Kinase 2Oxidative StressAntineoplastic AgentsAcute Kidney InjuryAnimalsMiceMice, KnockoutMaleMice, Inbred C57BLReactive Oxygen Species

Author keywords

G protein‐coupled receptor kinase 2 (GRK2)NADPH oxidase 4 (NOX4)acute kidney injury (AKI)chronic kidney disease (CKD)cisplatin

Substances

CisplatinNADPH Oxidase 4G-Protein-Coupled Receptor Kinase 2GRK2 protein, mouseAntineoplastic AgentsNox4 protein, mouseReactive Oxygen Species

Authors and institutions

  • Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Centre of A…
  • Center for Scientific Research, Anhui Medical University, Hefei, China.
  • Department of Nephrology, Hospital of Anhui Medical University, Hefei, China.
  • Department of Pharmacy, Hospital of Anhui Medical University (the First People's Hospital of Hefei), Hefei, China.

ORCID profiles: Qingtong Wang, Wei Wei, Chun Wang

Funding

  • Key Research and Development Plan of Anhui Province
  • Key Project of Provincial Natural Science Foundation of Universities in Anhui
  • Anhui Province Excellent Research and Innovation Team Project
  • University Synergy Innovation Program of Anhui Province
  • Anhui Medical University

Cite

APA

Duan, F., Ni, L., Wang, Q., Peng, J., Wang, X., Wang, Y., Hu, S., Kuai, J., Jiang, X., Wang, Q., Xu, B., Wei, W., & Wang, C. (2026). Inhibition of GRK2 mitigates cisplatin‐induced acute and chronic nephrotoxicity by targeting the NADPH oxidase 4/oxidative stress axis. British Journal of Pharmacology, 183(12), 3149-3172. https://doi.org/10.1111/bph.70348

Vancouver

Duan F, Ni L, Wang Q, Peng J, Wang X, Wang Y, et al. Inhibition of GRK2 mitigates cisplatin‐induced acute and chronic nephrotoxicity by targeting the NADPH oxidase 4/oxidative stress axis. British Journal of Pharmacology. 2026;183(12):3149-3172. doi:10.1111/bph.70348

BibTeX
@article{Duan2026,
  author = {Duan, Fei and Ni, Lei and Wang, Qianlei and Peng, Jie and Wang, Xueru and Wang, Yin and Hu, Shuoshuo and Kuai, Jiajie and Jiang, Xiao and Wang, Qingtong and Xu, Bingfa and Wei, Wei and Wang, Chun},
  title = {Inhibition of GRK2 mitigates cisplatin‐induced acute and chronic nephrotoxicity by targeting the NADPH oxidase 4/oxidative stress axis},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {12},
  pages = {3149--3172},
  doi = {10.1111/bph.70348}
}
Start for free →